DCVax Direct used in a patient with stage 4 pancreatic cancer whose chemotherapy was stoppedhttps://www.facebook.com/video.php?v=10100434831905439
(Video)The National Geographic channel ran a show called Stand Up to Cancer that aired on Friday, September 4.
On that show there was a two minute segment on a patient who was diagnosed with stage 4 pancreatic cancer. The patient, Allan Butler, is an employee of Nat Geo and this is how the story found its way into the segment.
Northwest Biotherapeutics (NWBO) was not involved in any way in the selection of Mr. Butler’s experience to be included in this program.
An important point of this segment is that it prominently shows and names the physician treating the patient, Dr. Ravi Murthy, and also shows and names the lead investigator for the phase 1 study of DCVax Direct, Dr. Vivek Subbiah. Both are physicians with M.D. Anderson.
"DCVax Direct was used in a patient with stage 4 pancreatic cancer whose chemotherapy was stopped.
The patient, a Nat Geo employee, is stable at 18 months post diagnosis and gives his very positive view of the efficacy of DCVax Direct.
Clinical studies show that 50% of such stage 4 pancreatic patients die within six months and 77% within one year. Perhaps as few as 2-3% survive 18 months.
M.D. Anderson doctors appeared in this segment. This prestigious institution is running the trial and is clearly supportive of DCVax Direct and NWBO.
This is just one patient, but it must be viewed alongside the recent impressive signal of efficacy seen in a sarcoma, another highly aggressive tumor.
The DCVax Direct trial is in its early days for reporting data and these two cases may yet prove to be outliers, but they are very encouraging. "here